Ruboxistaurin: PKC-β inhibition for complications of diabetes

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 17, 2009, Pages 2913-2925

  Danis, Ronald P ^a   Sheetz, Matthew J ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Diabetic macular edema; Diabetic nephropathy; Diabetic neuropathy; Diabetic retinopathy; Protein kinase C

Indexed keywords

PLACEBO; PROTEIN KINASE C; PROTEIN KINASE C BETA INHIBITOR; RUBOXISTAURIN; SCLEROPROTEIN; STAUROSPORINE; VASCULOTROPIN;

ATRIOVENTRICULAR BLOCK; BLINDNESS; BLOOD FLOW; BLOOD VESSEL PERMEABILITY; CLINICAL PRACTICE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERGLYCEMIA; IC 50; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY GRAFT; LEUKOSTASIS; LIMB AMPUTATION; MICTURITION; NONHUMAN; PERIPHERAL NEUROPATHY; PILOT STUDY; PREVALENCE; RETINOPATHY; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; THROMBOSIS; TREATMENT RESPONSE; UNITED STATES; URINARY URGENCY; VISUAL IMPAIRMENT;

DIABETES COMPLICATIONS; ENZYME ACTIVATION; HUMANS; INDOLES; MALEIMIDES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 73149112200     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903401620     Document Type: Review

References (102)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. In: Health USDo, and Human Services CfDCaP, editors. Atlanta; 2008
2. Diabetes Control and Complications Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329(14):977-986
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837-853
4. Walker EA, Molitch M, Kramer MK, et al Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program. Diabetes Care 2006;29(9):1997-2002
5. Chaturvedi N, Porta M, Klein R, et al Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebocontrolled trials. Lancet 2008;372(9647):1394-1402
6. Pogach LM, Brietzke SA, Cowan CL Jr, et al Development of evidence-based clinical practice guidelines for diabetes: the Department of Veterans Affairs/ Department of Defense guidelines initiative. Diabetes Care 2004;27 (Suppl 2):B82-9
7. Raikou M, McGuire A. The economics of screening and treatment in type 2 diabetes mellitus. Pharmacoeconomics 2003;21(8):543-564
8. Putzer GJ, Ramirez AM, Sneed K, et al Prevalence of patients with type 2 diabetes mellitus reaching the American Diabetes Association's target guidelines in a university primary care setting. South Med J 2004;97(2):145-148
9. Gardner TW, Antonetti DA. Ruboxistaurin for diabetic retinopathy. Ophthalmology 2006;113(12):2135-2136
10. Genuth S. Insights from the diabetes control and complications trial/ epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract 2006;12(Suppl 1):34-41 (Pubitemid 44963609)
11. Ceriello A, Ihnat MA, Thorpe JE. The "Metabolic Memory": is sore than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 2009;94(2):410-415
12. Narayanan S. Aldose reductase and its inhibition in the control of diabetic complications. Ann Clin Lab Sci 1993;23(2):148-158
13. Kitada M, Koya D, Sugimoto T, et al Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 2003;52(10):2603-2614
14. Nishikawa T, Edelstein D, Du XL, et al Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404(6779):787-790
15. Barile GR, Pachydaki SI, Tari SR, et al The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 2005;46(8):2916-2924
16. Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 2007;55(6):498-510
17. Ishii H, Jirousek MR, Koya D, et al Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996;272(5262):728-731
18. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998;47(6):859-866
19. King GL, Ishii H, Koya D. Diabetic vascular dysfunctions: a model of excessive activation of protein kinase C. Kidney Int Suppl 1997;52(Suppl 60):S77-85
20. Moore TC, Moore JE, Kaji Y, et al The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci 2003;44(10):4457-4464
21. Aiello LP, Bursell SE, Clermont A, et al Vascular endothelial growth factorinduced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997;46(9):1473-1480 (Pubitemid 27369086)
22. Koya D, Jirousek MR, Lin YW, et al Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997;100(1):115-126
23. Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci 1998;39(1):171-179
24. Hata Y, Rook SL, Aiello LP. Basic fibroblast growth factor induces expression of VEGF receptor KDR through a protein kinase C and p44/p42 mitogen-activated protein kinase-dependent pathway. Diabetes 1999;48(5):1145-1155
25. Yoshiji H, Kuriyama S, Ways DK, et al Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Research 1999;59(17):4413-4418
26. Yokota T, Ma RC, Park JY, et al Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes. Diabetes 2003;52(3):838-845
27. Nishizuka Y. The Albert Lasker Medical Awards. The family of protein kinase C for signal transduction. JAMA 1989;262(13):1826-1833
28. Shearman MS, Ase K, Saito N, et al Molecular heterogeneity and differential expression of multiple protein kinase C subspecies in central nervous tissue. Biochem Soc Trans 1988;16(4):460-463 (Pubitemid 18197844)
29. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988;334(6184):661-665 (Pubitemid 18197563)
30. Campochiaro PA. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci. 2004;45(3):922-931
31. Jirousek MR, Gillig JR, Gonzalez CM, et al (S)-13-[(dimethylamino)methyl] - 10,11,14,15-tetrahydro-4,9:16, 21- dimetheno-1H, 13H-dibenzo[e,k]pyrrolo [3,4-h][1,4,13]oxadiazacyclohexadecene- 1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem 1996;39(14):2664-2671
32. Engel GL, Farid NA, Faul MM, et al Salt form selection and characterization of LY333531 mesylate monohydrate. Int J Pharm 2000;198(2):239-247
33. Xia P, Inoguchi T, Kern TS, et al Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994;43(9):1122-1129
34. Kim YS, Kim BC, Song CY, et al Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-beta. J Lab Clin Med 2001;138(1):59-68
35. Lander HM, Tauras JM, Ogiste JS, et al Activation of the receptor for advanced glycation end products triggers a p21(ras)- dependent mitogen-activated protein kinase pathway regulated by oxidant stress. JBiol Chem 1997;272(28):17810-17814
36. Taher MM, Garcia JG, Natarajan V. Hydroperoxide-induced diacylglycerol formation and protein kinase C activation in vascular endothelial cells. Arch Biochem Biophys 1993;303(2):260-266
37. Mellor H, Parker PJ. The extended protein kinase C superfamily. Biochem J 1998;332(Pt 2):281-292
38. Keranen LM, Dutil EM, Newton AC. Protein kinase C is regulated in vivo by three functionally distinct phosphorylations. Curr Biol 1995;5(12):1394-1403
39. Edwards AS, Faux MC, Scott JD, Newton AC. Carboxyl-terminal phosphorylation regulates the function and subcellular localization of protein kinase C betaII. JBiol Chem 1999;274(10):6461-6468
40. Xia P, Aiello LP, Ishii H, et al Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996;98(9):2018-2026
41. Inoguchi T, Battan R, Handler E, et al Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992;89(22):11059-11063
42. Wu Y, Wu G, Qi X, et al Protein kinase C beta inhibitor LY333531 attenuates intercellular adhesion molecule-1 and monocyte chemotactic protein-1 expression in the kidney in diabetic rats. J Pharmacol Sci 2006;101(4):335-343
43. Aiello LP. The potential role of PKC beta in diabetic retinopathy and macular edema. Surv Ophthalmol 2002;47(Suppl 2):S263-9
44. Vinores SA, Derevjanik NL, Ozaki H, et al Cellular mechanisms of blood-retinal barrier dysfunction in macular edema. Doc Ophthalmol 1999;97(3-4):217-228
45. Vinores SA, Youssri AI, Luna JD, et al Upregulation of vascular endothelial growth factor in ischemic and nonischemic human and experimental retinal disease. Histol Histopathol 1997;12(1):99-109
46. Pe'er J, Folberg R, Itin A, et al Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 1998;105(3):412-416
47. Aiello LP, Avery RL, Arrigg PG, et al Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Eng J Med 1994;331(22):1480-1487
48. Ido Y, Chang KC, Lejeune WS, et al Vascular dysfunction induced by AGE is mediated by VEGF via mechanisms involving reactive oxygen species, guanylate cyclase, and protein kinase C. Microcirculation 2001;8(4):251-263
49. Pierce EA, Avery RL, Foley ED, et al Vascular endothelial growth factor/ vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995;92(3):905-909
50. Aiello LP, Pierce EA, Foley ED, et al Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92(23):10457-10461
51. Sledge GW Jr, Gokmen-Polar Y. Protein kinase C-beta as a therapeutic target in breast cancer. Semin Oncol 2006;33(3 Suppl 9):S15-8
52. Bursell SE, Takagi C, Clermont AC, et al Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats. Invest Ophthalmol Vis Sci 1997;38(13):2711-2720
53. Caballero AE, Arora S, Saouaf R, et al Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999;48(9):1856-1862
54. Mehta NN, Sheetz M, Price K, et al Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus. Cardiovasc Drugs Ther 2009;23(1):17-24
55. Chu S, Bohlen HG. High concentration of glucose inhibits glomerular endothelial eNOS through a PKC mechanism. Am J Physiol Renal Physiol 2004;287(3):F384-92
56. Bohlen HG, Nase GP. Arteriolar nitric oxide concentration is decreased during hyperglycemia-induced betaII PKC activation. Am J Physiol Heart Circ Physiol 2001;280(2):H621-7
57. Bohlen HG. Protein kinase betaII in Zucker obese rats compromises oxygen and flow-mediated regulation of nitric oxide formation. Am J Physiol Heart Circ Physiol 2004;286(2):H492-7
58. Beckman JA, Goldfine AB, Gordon MB, et al Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res 2002;90(1):107-111
59. Park JY, Takahara N, Gabriele A, et al Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes 2000;49(7):1239-1248
60. Koya D, Haneda M, Nakagawa H, et al Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000;14(3):439-447
61. McCarty MF. A central role for protein kinase C overactivity in diabetic glomerulosclerosis: implications for prevention with antioxidants, fish oil, and ACE inhibitors. Med Hypotheses 1998;50(2):155-165
62. Kohner EM, Patel V, Rassam SM. Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes 1995;44(6):603-607
63. Aiello LP, Clermont A, Arora V, et al Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 2006;47(1):86-92
64. Nakamura J, Kato K, Hamada Y, et al A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999;48(10):2090-2095
65. Casellini CM, Barlow PM, Rice AL, et al A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes Care 2007;30(4):896-902
66. Cameron NE, Cotter MA. Effects of protein kinase Cbeta inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid dysmetabolism. Diabetes Metab ResRev 2002;18(4):315-323
67. Park CW, Kim JH, Lee JH, et al High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-kappa B-dependent. Diabetologia 2000;43(12):1544-1553
68. Abiko T, Abiko A, Clermont AC, et al Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes 2003;52(3):829-837
69. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007;2007:95103
70. Tamura H, Miyamoto K, Kiryu J, et al Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005;46(4):1440-1444
71. Nonaka A, Kiryu J, Tsujikawa A, et al PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol VisSci 2000;41(9):2702-2706
72. Miyamoto K, Khosrof S, Bursell SE, et al Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 1999;96(19):10836-10841
73. Joussen AM, Poulaki V, Le ML, et al A central role for inflammation in the pathogenesis of diabetic retinopathy. Faseb J 2004;18(12):1450-1452
74. Kelly DJ, Chanty A, Gow RM, et al Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy. J Am Soc Nephrol 2005;16(6):1654-1660
75. Cagliero E, Roth T, Roy S, et al Expression of genes related to the extracellular matrix in human endothelial cells. Differential modulation by elevated glucose concentrations, phorbol esters, and cAMP. J Biol Chem 1991;266(22):14244-14250
76. Cagliero E, Roth T, Roy S, Lorenzi M. Characteristics and mechanisms of highglucose- induced overexpression of basement membrane components in cultured human endothelial cells. Diabetes 1991;40(1):102-110
77. Fumo P, Kuncio GS, Ziyadeh FN. PKC and high glucose stimulate collagen alpha 1 (IV) transcriptional activity in a reporter mesangial cell line. Am J Physiol 1994;267(4 Pt 2):F632-8
78. Nakamura T, Miller D, Ruoslahti E, Border WA. Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factorbeta 1. Kidney Int 1992;41(5):1213-1221
79. Gilbert RE, Kim SA, Tuttle KR, et al Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care 2007;30(4):995-996
80. Ohshiro Y, Ma RC, Yasuda Y, et al Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbetanull mice. Diabetes 2006;55(11):3112-3120
81. Stasek JE, Jr., Patterson CE, Garcia JG. Protein kinase C phosphorylates caldesmon77 and vimentin and enhances albumin permeability across cultured bovine pulmonary artery endothelial cell monolayers. J Cellular Physiol 1992;153(1):62-75
82. Kelly DJ, Buck D, Cox AJ, et al Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy. American Journal of Physiology. Renal Physiol 2007;293(2):F565-74
83. Williams B, Gallacher B, Patel H, Orme C. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997;46(9):1497-1503
84. Vinik AI, Bril V, Litchy WJ, et al Sural sensory action potential identifies diabetic peripheral neuropathy responders to therapy. Muscle Nerve 2005;32(5):619-625
85. Brooks B, Delaney-Robinson C, Molyneaux L, Yue DK. Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin. J Diabetes Complications 2008;22(2):88-95
86. Vinik AI, Bril V, Kempler P, et al Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Therap 2005;27(8):1164-1180
87. Tesfaye S, Tandan R, Bastyr EJ III, et al Factors that impact symptomatic diabetic peripheral neuropathy in placeboadministered patients from two 1-year clinical trials. Diabetes Care 2007;30(10):2626-2632
88. Advance Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358(24):2560-2572
89. Viberti G, Chaturvedi N. Angiotensin converting enzyme inhibitors in diabetic patients with microalbuminuria or normoalbuminuria. Kidney Int Suppl 1997;63:S32-5
90. Tuttle KR, Bakris GL, Toto RD, et al The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005;28(11):2686-2690
91. Tuttle KR, McGill JB, Haney DJ, et al Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin J Am Soc Nephrol 2007;2(4):631-636
92. Klein R, Knudtson MD, Lee KE, et al The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twentyfive- year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008;115(11):1859-1868
93. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103(12):1796-1806
94. Early Treatment Diabetic Retinopathy Study Research Group. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Ophthalmology 1991;98(5 Suppl):807-822
95. National Society to Prevent Blindness. Vision problems in the U.S. Data analysis. Definitions, data sources, detailed data tables, analysis, interpretation. National Society to prevent blindness. New York; 1980
96. PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005;54(7):2188-2197
97. PKC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 2007;125(3):318-324
98. Aiello LP, Davis MD, Girach A, et al Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006;113(12):2221-2230
99. Davis MD, Sheetz MJ, Aiello LP, et al Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Invest Ophthalmol Vis Sci 2009;50(1):1-4, [Epub 15 Aug 2008]
100. McGill JB, King GL, Berg PH, et al Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin. Expert Opin Drug Safety 2006;5(6):835-845
101. DCCT Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Arch Ophthalmol 1998;116(7):874-886
102. White NH, Sun W, Cleary PA, et al Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008;126(12):1707-1715